Tests Gliatamin for low mood in people with type 2 diabetes
Tests Gliatamin against a placebo tablet in adults with type 2 diabetes and low mood.
Key facts
- Who runs it
- Yonsei University
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 60 people, planned
- Started
- 1 Jun 2016
- Planned end
- 30 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Chonline Alphoscerate
- Placebo Oral Tablet
- Record updated
- 24 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 or older with type 2 diabetes and mild to moderate low mood. It tests whether Gliatamin (choline alphoscerate) helps their mood.
- Age
- 50 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with HbA1c of 10.0% (86 mmol/mol) or lower. Depression score (Beck Depression Inventory) from 10 up to less than 30 points.
- Earlier treatment
- People already on dementia treatment or anti-depression medication cannot join.
- Biomarker or test result
- HbA1c 10.0% (86 mmol/mol) or lower. Beck Depression Inventory score of at least 10 and below 30.
Main reasons for not taking part
- Type 1, secondary or gestational diabetes
- Dementia treatment or anti-depression medication now
- Uncontrolled psychiatric disorder or Beck Depression Inventory score of 30 or more
- Chronic liver disease or abnormal liver function
- Kidney failure, moderate or severe kidney impairment, or dialysis
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Type 2 diabetic patients
- Age ≥ 50
- Glycemic control: HbA1c ≤ 10.0%
- 10 ≤ Beck Depression Inventory (BDI) <30 points
- Participants who can undergo contraception in case of being in childbearing period
- Understands the study procedure, alternatives, and risks and voluntarily agrees to participate by giving written informed concent
Who cannot take part
- History of alcohol or drug abuse in the previous 3 months
- Type 1 diabetes, Secondary diabetes, gestational diabetes
- Ongoing dementia treatment or anti-depressive disorder medication
- Uncontrolled psychiatric disorder
- Underlying chronic liver disease (hemochromatosis, liver cell carcinoma, autoimmune liver disease, liver cirrhosis, chronic viral hepatitis)
- Allergy or hypersensitivity to target medication or any of its components
- Renal failure, moderate or severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m2), or ongoing dialysis
- Human immunodeficiency virus (HIV) or human immunodeficiency virus (AIDS)
- chronic pancreatitis or pancreatic cancer
- Abnormal liver function (AST/ALT > x3 upper normal limit)
- BDI ≥ 30 points
- Heavy alcoholics
- Premenopausal women who are nursing or pregnant
Where in South Korea
- Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes CenterSeoul, South KoreaContact: Bong Soo Cha, MDTaking people
About the trial
What the trial wants to find out
The aim of this study is to investigate the effect of Gliatamin (chonline alphoscerate) on depressive mood in type 2 diabetes patients and demonstrate the impact of improved depressive mood could be influence the patient's quality of life and glycemic control.
The 2 groups in the trial
- GlitaminTreatment being tested
800mg/day
Treatment: Chonline Alphoscerate
- PlaceboPlacebo, for comparison
same shape, color, size tablet as Glitamin
Treatment: Placebo Oral Tablet
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients
- Plain-language title
- Tests Gliatamin for low mood in people with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 24 February 2025